| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02373865 Details | 2019-02-27 Interventional | 4 | 4 | Glimepiride Sitagliptin Pho… Diabetes Mellit… Diabetes Mellit… Hypoglycemia Diabetes Mellit… | Premature termination due to insufficient patient recruitement.. Limitations of the study: deceleration of patient recruitment, break up of patient recruitment, descriptive reporting of patient characteristics of 4 enrolled patients (no statistically reliable results are available) | |||
| NCT00920556 Details | 2019-02-27 Interventional | 2 | 24 | Bortezomib Multiple Myelom… Neoplasms, Plas… | Study terminated.24 subjects enrolled;provided adequate data for decision making. The study of Multiple Myeloma, was terminated early due to minimal efficacy signal observed. | |||
| NCT00315913 Details | 2019-02-27 Interventional | 2 | 0 | Propranolol Dystocia Dysfunctional L… | Lack of feasibility - | |||
| NCT01168908 Details | 2019-02-26 Interventional | 2 | 20 | Sildenafil Citr… Muscular Dystro… Muscular Dystro… Becker Muscular… Duchenne Muscul… | As recommended by the DSMB. - | |||
| NCT02973399 Details | 2019-02-22 Interventional | 1 | 5 | Ibrutinib Cancer | Low recruitment - | |||
| NCT02873702 Details | 2019-02-22 Interventional | 3 | 37 | Dexlansoprazole Lansoprazole Esophagitis Erosive Esophag… | Compound is not expected to change the current treatment practice or fill significant clinical
need for patients in China over currently available EE agents. - | |||
| NCT02123264 Details | 2019-02-22 Interventional | 3 | 28 | Zoledronic Acid Arthritis Arthritis, Rheu… | - - | |||
| NCT00913393 Details | 2019-02-22 Interventional | 2 | 46 | Antibodies, Mon… Diabetes Mellit… Diabetes Mellit… Diabetic Nephro… Kidney Diseases Diabetic Kidney… Diabetic Nephro… Type 2 Diabetes… | Study was terminated early for business purposes and as a result of a strategic decision to
shift focus to another indication. - | |||
| NCT03361124 Details | 2019-02-21 Interventional | 4 | 0 | Oxytocin Anemia Hemorrhage Uterine Inertia Blood Loss Anem… Uterine Atony W… | Investigator no longer interested in proceeding with study - | |||
| NCT02708160 Details | 2019-02-21 Interventional | 2 | 0 | Fluorides Dental Caries | Withdrawn due to business reasons - | |||
| NCT02561832 Details | 2019-02-20 Interventional | 1 | 15 | Carboplatin Cyclophosphamid… Olaparib Breast Neoplasm… Breast Cancer | This decision was based upon strategic considerations impacting the clinical development of
olaparib in this indication. Early termination leading to a small number of subjects analyzed (N=15). | |||
| NCT01195974 Details | 2019-02-20 Interventional | 1 | 13 | Drospirenone an… Acquired Immuno… Communicable Di… HIV Infections Infections Infection, Huma… | In a Phase II study in HIV-infected patients there were a number of seizures, although exact
causality could not be assessed phase 1 activity was terminated. - | |||
| NCT03146403 Details | 2019-02-19 Interventional | 2 | 33 | Vaccines Communicable Di… Herpes Genitali… Herpes Simplex Herpesviridae I… Infections Genital Herpes HSV-2 Infection | 2017 business decision to cease GEN-003 spending. Small numbers of enrolled subjects likely led to a lack of statistical power. After a 2017 business decision to cease GEN-003 spending, the outcome measures were reduced to 6 months of follow up, rather than the originally planned 12 months. | |||
| NCT01376310 Details | 2019-02-19 Interventional | 2 | 159 | Carboplatin Docetaxel Erlotinib Hydro… Everolimus Gemcitabine Paclitaxel Pemetrexed Trametinib Cancer | Company Decision - | |||
| NCT02662036 Details | 2019-02-18 Interventional | 4 | 70 | Bupivacaine Mammaplasty | Interim analysis showed that there was no difference between the two drugs - | |||
| NCT00836927 Details | 2019-02-18 Interventional | 2 | 7 | Sirolimus Neoplasms Advanced Cancer… | - - | |||
| NCT02620384 Details | 2019-02-15 Interventional | 3 | 147 | Metolazone Heart Failure Acute Decompens… | Limited resources available to met accrual goal. Recruitment ended early due to limited resources,however all protocol directed measures were completed for all enrolled. I&O was measured and recorded manually which introduces room for error.BORG assessment timing not exact due to limited resources. | |||
| NCT02409355 2014-003106-33 Details | 2019-02-15 Interventional | 3 | 8 | Atezolizumab Carboplatin Gemcitabine Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | The study was closed due to low patient enrollment and the Sponsor's decision to include
patients with squamous NSCLC into the GO29431 study, NCT02409342. The study was closed due to low enrollment and the Sponsor's decision to include patients with squamous NSCLC into the GO29431 study. | |||
| NCT01841307 Details | 2019-02-15 Interventional | 1 | 16 | Cromolyn Sodium Gastroesophagea… Idiopathic Pulm… Pulmonary Fibro… Respiratory Asp… Lung Transplant… | Difficulty recruiting; Funding ended; interim analysis provided sufficient data for
interpretation. - | |||
| NCT01587222 Details | 2019-02-15 Interventional | 2 | 0 | Midodrine Octreotide Hepatorenal Syn… Renal Insuffici… Fibrosis Renal Failure | the sponsor did not provide the treatment - |